1Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the antihypertensive and lipid-Lowering treatment to prevent heart attack Trial (ALLHAT)[J]. Hypertension,2003,42(3):2392-46.
3Wilson TA,Foxall TL,Nicolosi RJ,et al. Doxazosin,an alpha-1 antagonist prevents further progression of the advanced atherosclerotic lesion in hypercholesterolemic hamsters[J]. Metabolism,2003,52(10):1240-1245.
5Brude IR,Drevon CA,Viken K,et al.Doxazosin treatment and peroxidation of low-density lipoprotein among male hypertensive subjects: in vitro and ex vivo studies[J]. Biochem Pharmacol,1999,58(1):183-191.
6Tamasawa N,Matsui J,Ogawa Y,et al.Effect of doxazosin on the size of LDL particle in the type 2 diabetic patients with hypertension[J]. J Diabetes Complications,2000,14(3):135-139.
7Hirano T,Yoshino G,Kashiwazaki K,et al. Doxazosin reduces prevalence of small dense low density lipoprotein and remnan-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients[J]. Am J Hypertens,2001 ,14(9/1):908-913.
8Lopez Farre A,Rodriguez Feo JA,Garcia-Colis E,et al.Reduction of the soluble cyclic GMP vasorelaxing system in the vascular wall of stroke-prone spontaneously hypertensive rats: effect of the alpha1-receptor blocker doxazosin[J]. J Hypertens,2002,20(3):371-373.
9Courtney CH,McCance DR,Atkinson AB,et al.Effect of the alpha-adrenergic blocker,doxazosin,on endothelial function and insulin action[J]. Metabolism,2003,52(9):1147-1152.
10Komai N,Ohishi M,Moriguchi A,et al.Low-dose doxazosin improved aortic stiffness and endothelial dysfunction as measured by noninvasive evaluation[J]. Hypertens Res,2002,25(1):5-10.
二级参考文献7
1[7]Vashisht R, Sian M, Franks PJ, et al. Long-term reduction of intimal hyperplasia by the selective alpha-1 adrenergic antagonist doxazosin. Br J Surg, 1992, 79: 1 285-288
3[2]Hu ZW, Shi XY, Okazaki M, et al. Angiotensin Ⅱ induces transcription and expression of α1 -adrenergic receptors in vascular soomth muscle cells. Am J Physiol, 1995, 268: H1 006-014
4[3]Hu ZW, Shi XY, Lin R, et al. α1-Adrenergic receptor subtypes: activation of phosphatidylinositol 3-kinase. Mol Biol Cell Suppl, 1995, 6: 128
5[4]Ulrich K, Shu W, Sarah K, et al. Doxazosin inhibits retinoblastoma protein phosphorylation and G1-S transition in human coronary smooth muscle cells. Arterioscler Thromb Vasc Biol, 2000, 20: 1 216-224
6[5]Kato JY, Matsuoka M, Polyak K, et al. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell, 1994, 79: 487-496
7[6]Laufs U, Marra D, Node K, et al. 3 Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem, 1999, 274: 21 926-931
3Djavan B. α1-Adenoceptor antagonists for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia(LUTS/BPH) [ J ]. European Urology Supplements, 2004, 34(4) :23-30.
4Mann SJ, Gerber LM. Low-dose alpha/beta blockade in the treatment of essential hypertension [J]. Am J. Hypertens,2001, 14(6pt1 ) :553-558.
5Koo J, Avakian S, Martin G J. Derivatives of 1, 4- Benzodixan-2-carboxamides [J]. J. Am. Chem. Soc., 1955, 77:5373-5375.
6Vashisht R,Sian M, franks PJ,et al. Long-term reduction of intimal hyperplasia by the selective alpha-1 adrenergic antagonist doxazosin[J]. Br J Surg,1992,79(11):1285-1288.
7Wilson TA, Foxall TL, Nicolosi R J, et al. Doxazosin, an alpha-1 antagonist prevents further progression of the advanced atherosclerotic lesion in hypercholesterolemic hamsters[J]. Metabolism,2003,52(10):1240-1245.
8Glanz M,Garber AJ,Mancia G,et al, Meta-analysis of studies using selective alpha1-blockers in patients with hypertension and type 2 diabetes[J]. Int J Clin Pract,2001,55(10):694-701.
9Wilson TA,Foxall TL,Nicolosi RJ, Doxazosin, an alpha-1 antagonis, prevents further progression of the advanced atherosclerotic lesion in hypercholesterolemic hamsters[J]. Metabolism,200S,52(10):1240-1245.
10Kinoshita M,Shimazu N,Fujita M,et al. Doxazosin, an alpha1-adrenergic antihypertensive agent, decreases serum oxidized LDL[J]. Am J Hypertens, 2001,14(3): 267-270.
